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Abstract
Inﬂammation underlies a wide variety of physiological and pathological processes. Acute inﬂammation is the initial response of the
body to harmful stimuli. Chronic inﬂammation, by contrast, is a prolonged, dysregulated and maladaptive response that involves active
inﬂammation, tissue destruction and attempts at tissue repair. Over the past few years, such persistent inﬂammation has been shown
to be associated with pulmonary hypertension (PH). Substantial advances in basic and experimental science have illuminated the role
of inﬂammation and the underlying cellular and molecular mechanisms that contribute to PH. This review summarizes the experimen-
tal and clinical evidence for inﬂammation in various types of PH. In addition, it assesses the current state of knowledge regarding
the inducers/triggers of chronic inﬂammation and infection, as well as the inﬂammatory mediators and cells that are involved in PH.
Inﬁltration of inﬂammatory cells, such as dendritic cells, macrophages, mast cells, T-lymphocytes and B-lymphocytes, in the vascular
lesions and an elevation of serum/tissue concentrations of proinﬂammatory cytokines and chemokines and their contribution to
pulmonary vascular remodelling are reported in detail. We review the data supporting the use of inﬂammatory markers as prognos-
tic and predictive factors in PH. Finally, we consider how new insights into inﬂammation in PH may identify innovative therapeutic
strategies.
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Pathogenesis of Pulmonary Hypertension
Pulmonary hypertension (PH) is a progressive disease with a
poor prognosis that results in right heart dysfunction and
right heart failure [1]. Characterized by increased pulmonary
vascular resistance, PH includes a heterogeneous group of
clinical entities that have been subcategorized into ﬁve
groups on the basis of association with other diseases,
according to the currently accepted PH classiﬁcation [2].
Group 1, pulmonary arterial hypertension (PAH), is com-
posed of a heterogeneous group of diseases that have been
subcategorized as idiopathic PAH (IPAH), familial PAH, PH
associated with other diseases, such as connective tissue
diseases (e.g. systemic sclerosis), portopulmonary hyperten-
sion, and PH related to human immunodeﬁciency virus (HIV)
infection, drugs and toxins [2].
The pathogenesis of PH is a complex, multifactorial process.
Increased pulmonary arterial pressure in PH patients may
result from a combination of pulmonary vasoconstriction,
inward vascular wall remodelling and in situ thrombosis, lead-
ing to increased vascular stiffness as well as narrowing of the
vascular lumen [1]. However, the exact triggers of PH have
not been identiﬁed yet. An initial insult, from chronic hypoxia,
inﬂammation, viral infection, mechanical stretch, shear stress,
and/or unknown factors, is considered to activate or affect the
endothelium. This results in altered production of endothelial
mediators and release of inﬂammatory mediators, which have
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been increasingly implicated in PH [3]. These inﬂammatory
mediators, including cell adhesion molecules, cytokines,
chemokines and growth factors, direct the recruitment of
inﬂammatory cells and propagate a number of inﬂammatory
pathways that lead to vascular cell proliferation, migration and
extracellular matrix deposition, all of which contribute to the
structural remodelling-characteristic of PH [4,5] (Fig. 1).
Inﬂammatory processes are prominent in various forms of
PH, and are increasingly recognized as major pathogenic
components of pulmonary vascular remodelling in IPAH or
PAH related to more classical forms of inﬂammatory
syndromes, such as connective tissue diseases, HIV infection,
or other viral aetiologies. Similarly, inﬂammation seems to
play a signiﬁcant role in experimental animal models of PH.
This review will focus on inﬂammatory processes that are
involved in the initiation or progression of PH, and the prog-
nostic and therapeutic importance of inﬂammation in PH.
An Overview of Inﬂammation (Acute and
Chronic)
Inﬂammation is an adaptive response that is triggered by
noxious stimuli and conditions, such as infection and tissue
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FIG. 1. Schematic illustration of infec-
tion-mediated and inﬂammation-medi-
ated vascular remodelling: In response
to infection and inﬂammatory events,
lung vascular cells produce inﬂammatory
mediators (chemokines and cytokines),
thereby recruiting the inﬂammatory cells
(macrophages, dendritic cells, mast cells,
B-cells, T-cells and regulatory T-cells).
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mediators, inﬂammatory cells may per-
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VEGF, vascular endothelial growth
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injury [6]. It is characterized by the sequential release of
cytokines, chemokines and growth factors that regulate
increased vascular permeability and recruitment of leuko-
cytes. Increased vascular permeability also results in extrava-
sation of plasma proteins, which further amplify the
inﬂammatory reaction. Importantly, regardless of the cause,
inﬂammation presumably evolved as an adaptive response for
restoring homeostasis. However, when inﬂammation persists
(chronic inﬂammation), it can cause tissue damage and loss
of function. Chronic inﬂammation may occur because of the
persistence of infection or antigen, recurring tissue injury, or
a failure of endogenous anti-inﬂammatory mechanisms that
drive the resolution of inﬂammation [6].
Notably, altered interactions between adaptive and innate
immune cells can lead to chronic inﬂammation. It is generally
thought that, during acute inﬂammation, innate immune cells,
such as dendritic cells (DCs), natural killer cells, macrophag-
es, neutrophils, basophils, eosinophils and mast cells, form
the ﬁrst line of immune defence and regulate the activation
of adaptive immune responses. By contrast, during chronic
inﬂammation, these roles can be reversed—adaptive immune
responses by adaptive immune cells, such as B-lymphocytes,
CD4+ helper T-lymphocytes and CD8+ cytotoxic T-lympho-
cytes, can cause ongoing and excessive activation of innate
immune cells [7].
The Scientiﬁc Basis of Inﬂammation in PH
The concept that immunological reactions in PH play a signif-
icant role in the development and worsening of the disease
is now well accepted. Autoimmune inﬁltration of immune
cells and inﬂammatory reactions have been shown to con-
tribute to the pathogenesis of IPAH [4,5,8].
Inﬂammatory and Immune Cell
Component of PH
The inﬂammatory and immune component of structurally
altered vessels includes circulating monocytes, neutrophils,
DCs, macrophages and lymphocytes, as well as ﬁbroblasts,
resident endothelial cells and smooth muscle cells. Presum-
ably, circulating cells are directed to sites of injury, adhere
to or come close to endothelial cells, invade the internal
elastic lamina, and release a variety of substances that act on
the local environment and promote chemotaxis. Released
cytokines and growth factors produce the effects of inﬂam-
mation by mediating communication between and among cir-
culating and resident vascular cells. Finally, all of these
interactions result in vascular remodelling through matrix
remodelling, collagen deposition, proliferation and migration
of all vascular cell types [9] (Fig. 1).
Innate Immune Cells
DCs
DCs, which are crucial for the activation of naive T-cells, play
an important role as professional antigen-presenting cells in
the immune system. Perros et al. [10] demonstrated immature
DC population inﬁltrating vascular lesions in both IPAH
patients and in experimental PH. Accumulation of these pro-
fessional antigen-presenting cells may involve presentation of
antibodies to endothelial cells, ﬁbroblasts and nuclear antigens
that are found in the serum of patients with IPAH and collagen
vascular disease-associated PAH [11,12]. Recently, Wang et al.
[13] reported a decrease in the percentage of monocyte-
derived DCs in the peripheral blood of IPAH patients, sugges-
ting a Th1 immune reaction in the pathogenesis of IPAH.
Mast cells
Mast cells are major effector cells in allergy and host defence
responses. Upon activation, mast cells release a broad spec-
trum of proinﬂammatory cytokines, growth factors, vasoac-
tive substances and proteases (tryptase and chymase).
Although vascular mast cells are rare in the normal vascula-
ture, an increase in the number of vascular mast cells was
found in patients with PH as well as in experimental models
of PH [14,15]. It is postulated that mast cells are a rich
source of interleukin (IL)-4, as well as other factors that are
capable of stimulating autoreactive B-cells to secrete auto-
antibodies, including anti-endothelial cell antibodies, and mast
cell degranulation through regulation of matrix metallo-
protease activity appears to be an important factor in the
initial phase of pulmonary vascular remodelling [16].
Macrophages/monocytes
Recruitment of macrophages, along with other mononuclear
cells, has been reported in primary PH as well as in second-
ary forms of PH, including high-ﬂow congenital heart disease,
scleroderma, and PH-associated acute respiratory distress
syndrome [17,18]. Similarly, increased numbers of macro-
phages and neutrophils have been described in murine and
rat lungs in response to chronic hypoxia and monocrotaline
(MCT) [19,20]. Although the molecular mechanism of mono-
cyte/macrophage inﬁltration and its roles remain elusive,
macrophage accumulation and activation in remodelled
pulmonary vessels may lead to the release of a variety of
proinﬂammatory cytokines, (e.g. monocyte chemotactic
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protein (MCP-I) and matrix metalloproteases) that are capa-
ble of causing vasoconstriction, increasing vascular permeabil-
ity and inducing proliferation [21].
Adaptive Immune Cells
B-lymphocytes
B-lymphocytes (B-cells) are fundamental to the humoral
immune response, because of their potential to differentiate
into antibody-producing plasma B-cells. B-cells also play a cru-
cial role in cell-mediated immune regulation through antigen
presentation, production of various cytokines, differentiation
of T-effector cells, and collaboration with antigen-presenting
DCs [8]. Antibodies directed against pulmonary endothelial
cells and ﬁbroblasts have been found in PAH, suggesting a role
of B-cells in PAH [11,12]. In corroboration, activation of
B-cells in peripheral blood B-lymphocytes and perivascular
inﬁltration of B-lymphocytes has been observed in patients
with IPAH [17,22].
T-lymphocytes (cytotoxic T-cells, helper T-cells and regula-
tory T-cells (Treg cells))
Inﬁltration of T-lymphocytes has been previously noted in
lungs of IPAH patients [17]. Bonnet et al. [23] reported CD3+
T-lymphocytes with activated NFATc2 (a nuclear Ca2+/
calceneurin-sensitive transcription factor found in T-lympho-
cytes) in the walls of resistance arteries in IPAH patients.
Recent studies by Austin et al. [24] support these ﬁndings,
suggesting a preponderance of CD3+ and CD8+ T-lympho-
cytes in the peripheral lung of PAH patients. Animal studies
also implicate the lymphocyte in the pathogenesis of PAH.
Athymic rats, which lack T-cells, were shown to develop
obliterative vascular lesions when treated with a vascular
endothelial growth factor receptor blocker under normoxic
conditions, suggesting a protective role of T-lymphocytes in
pulmonary vascular remodelling [25].
On the other hand, Daley et al. [26] demonstrated that
depletion of CD4+ T-cells, the antigen-speciﬁc T-helper type 2
(Th2) response or the pathogenic Th2 cytokine IL-13 signiﬁ-
cantly ameliorated pulmonary arterial muscularization. Treg
cells control the balance between Th1 and Th2 responses,
and are implicated in the maintenance of self-tolerance and
control of autoimmunity. In addition, Treg cells can inﬂuence
B-cell responses. Recent studies have shown that IPAH
patients have a higher proportion of circulating Treg cells
than controls, suggesting altered immune control by CD4+
T-lymphocytes [27]. However, the proportion of these cells
in the hypertensive pulmonary vasculature remains to be
investigated.
Mediators and Effectors of Inﬂammation
Inducers of inﬂammation trigger the production of numerous
inﬂammatory mediators, which in turn alter the function of
many tissues and organs. Inﬂammatory mediators can be
derived from plasma proteins or secreted by circulating and
resident cells of the vasculature. These mediators can be
vasoactive amines, vasoactive peptides, fragments of comple-
ment components, lipid mediators, cytokines, chemokines or
proteolytic enzymes [7,9]. Chemotactic cytokines play a role
in leukocyte recruitment and trafﬁcking in PH, such as roll-
ing, activation, adhesion and extravasation into the inﬂamed
tissue along a chemoattractant gradient involving chemokines
(soluble, secreted basic proteins). An elevation of serum
concentrations of proinﬂammatory cytokines and local
expression of chemokines can be found in IPAH patients.
IL-1, IL-6 and tumour necrosis factor-a (TNF-a)
Patients with idiopathic or associated PAH exhibit higher
circulating levels and pulmonary expression of IL-1b, IL-6 and
TNF-a than healthy controls [28]. Voelkel et al. studied the
role of IL-1, a strong proinﬂammatory cytokine, in MCT-
induced PH as compared with chronic hypoxia PH. IL-1 was
produced in excessive amounts in the lungs of rats treated
with MCT [29]. Repeated injections of an IL-1 receptor
antagonist reduced PH and right heart hypertrophy in the
MCT model but not in the chronic hypoxia model. Humbert
et al. [28] found elevated circulating levels of IL-1 and IL-6 in
serum of patients displaying severe PAH, and therefore pos-
tulated a possible role for mediators of inﬂammation in some
forms of PH. Recently, transgenic mice overexpressing IL-6
have been shown to develop spontaneous pulmonary vascu-
lar remodelling and PH [30]. It was also reported that trans-
genic mice overexpressing TNF-a develop severe PH and
right ventricular hypertrophy [31].
Fractalkine
Fractalkine (CX3CL1) exists in a membrane-bound form (as
a cell adhesion molecule on endothelial cells) or a soluble
form (as a chemotactic protein) after shedding from the cell
surface, and is therefore a structurally distinct chemokine. It
mediates its effects through CX3CR1, a seven-transmem-
brane receptor that is expressed by monocytes, DCs, mi-
croglial cells, neurons, natural killer cells, mast cells, and
subpopulations of T-lymphocytes. Balabanian et al. [32]
found not only that fractalkine is upregulated in circulating
CD4+ and CD8+ T-lymphocytes from PAH patients as com-
pared with control subjects, but also that these patients
displayed elevated soluble fractalkine plasma concentrations.
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Furthermore, PAH lung samples showed increased fractalkine
mRNA expression as compared with controls, and pulmo-
nary artery endothelial cells from PAH patients expressed
fractalkine [32]. Perros et al. [33] demonstrated that fractal-
kine was expressed by inﬂammatory cells surrounding plexi-
form lesions, and that pulmonary smooth muscle cells from
these vessels exhibited increased fractalkine expression.
Furthermore, it was shown that cultured rat pulmonary
artery smooth muscle cells expressed CX3CR1 and that
fractalkine induced proliferation, but not migration, of these
cells, indicating that fractalkine may act as a growth factor
for pulmonary artery smooth muscle cells [33].
RANTES
RANTES (regulated upon activation, normal T-cell expressed
and secreted; CCL5) recruits leukocytes, including T-cells
and monocytes, through different chemokine receptors
(CCRs) (e.g. CCR1, CCR3 and CCR5). In lung samples from
PAH patients, the mRNA expression of RANTES was
increased as compared with control subjects, and Dorfmu¨ller
et al. [34] proposed that it might originate from endothelial
cells. Further investigations are needed to assess the exact
relevance of these ﬁndings for the pathophysiology of PAH.
MCP-1/CCR2
MCP-1 (CCL2) is one of the most relevant cytokines synthe-
sized by vascular cells, and is a potent mediator of the activa-
tion of monocytes and macrophages. Its effects are mediated
by CCR2, which is expressed by various cell types, including
monocytes and vascular smooth muscle cells. MCP-1 activates
monocytes and macrophages, thereby leading to induction of
cytokine secretion and expression of adhesion molecules. As
compared with healthy controls, IPAH patients exhibit
increased levels of MCP-1 in the plasma as well as in lung tis-
sue [21]. In addition, elevated release of MCP-1 by pulmonary
endothelial cells and pulmonary arterial smooth muscle cells
has been demonstrated [35]. The migration rate of mono-
cytes was signiﬁcantly increased in the absence of pulmonary
endothelial cells (particularly in IPAH patients) and was signiﬁ-
cantly decreased by MCP-1-blocking antibodies [35]. Finally,
pulmonary arterial smooth muscle cells of PAH patients
display an increased migratory and proliferative response to
stimulation with MCP-1 as compared with healthy controls,
suggesting an important role of MCP-1 in PH.
Stromal cell-derived factor-1a (SDF-1a)
SDF-1a (CXCL12) is a small cytokine belonging to the
chemokine family. SDF-1a activates leukocytes, and is often
induced by proinﬂammatory stimuli such as lipopolysaccha-
rides, TNF-a and IL-1. Recently, the role of SDF-1a and its
receptor CXCR4 in neonatal hypoxia-induced PH was
described by Young et al. [36]. They demonstrated that inhi-
bition of the SDF-1a–CXCR4 axis decreased the expression
of progenitor cells in the lungs and right ventricles of treated
mice, as well as decreasing pulmonary vascular cell prolifera-
tion and apoptosis and preventing the development of
hypoxia-induced pulmonary vascular remodelling in neonatal
mice [36].
Triggers for Inﬂammation—role of
Infection
Although the concept that inﬂammation occupies a central
position in the pathophysiology of PH has gained considerable
currency, knowledge of the inciting factors remains remark-
ably sketchy. Apart from exogenous and endogenous inducers
of inﬂammation, infectious agents (e.g. viruses and parasites)
might also conceivably furnish inﬂammatory stimuli in PH.
Viral infection
HIV. HIV infection is one of the risk factors for PH. The lit-
erature suggests that the inﬂammatory and immune cells are
major players in pulmonary vascular pathogenesis, where
cytokines, growth factors and viral proteins may act as
potential mediators [37]. However, the underlying patho-
mechanism is not precisely known.
Human herpes virus (HHV)-8. HHV-8, a vasculotropic c-herpes
virus, is associated with angioproliferative disorders such as
Kaposi’s sarcoma and multicentric Castleman’s disease. Cool
et al. suggested a potential association of HHV-8 infection
with the development of the plexiform lesion of pulmonary
vessels, but this relationship was contradicted by others
[38,39]. Although it is still controversial, recent in vitro stud-
ies have demonstrated that HHV-8 infection signiﬁcantly
changes the gene expression pattern of pulmonary vascular
endothelial cells in the direction of inﬂammation, prolifera-
tion, angiogenesis, matrix remodelling and apoptosis [40].
Such alterations in cell signalling as are induced by HHV-8
infection are implicated in pulmonary vascular remodelling.
Nevertheless, caution must be exercised until these ﬁndings
have been conﬁrmed in vivo in animal model studies, and the
links between HHV-8 infection and pulmonary vascular patho-
genesis have been established.
Hepatitis C virus (HCV). HCV infection is a leading cause of
chronic liver disease. The infection is associated with multi-
ple extrahepatic manifestations, including PH. PH complicates
HCV infection in 1–5% of patients with chronic liver
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diseases, and the majority of the patients are diagnosed
with portal hypertension before PH [41,42]. Although the
pathogenesis of portopulmonary hypertension is poorly
understood, the histopathology of pulmonary vessels is com-
parable with that of IPAH [41]. It is as yet unknown whether
there is a direct role of viral factors, or whether the vascular
lesions develop secondarily to increased vasoconstrictive,
proliferative or inﬂammatory mediators owing to the infec-
tion-induced impaired hepatic metabolism and portosystemic
shunting. Moreover, in the context of HCV infection being
common among the population living with HIV infection and
the progression of HCV disease being accelerated in
HIV–HCV co-infection [43], future studies are warranted to
elucidate the role of HCV infection as well as HIV–HCV
co-infection in pulmonary vascular pathology.
Parasitic infection
Schistosoma infection. The pulmonary vascular pathology
characterized by intimal, medial and adventitial thickening,
perivascular inﬂammatory cells and complex plexiform
lesions is observed in chronic schistosomiasis, a disease
caused by an infection with a parasitic trematode of the
genus Schistosoma. The parasitic egg burden on the lung
tissue and the consequent induction of inﬂammatory and
immune processes have been implicated in the pathogenesis
[44,45]. However, the precise pathomechanism is as yet
incompletely understood.
Other parasitic infections. Associations of Wuchereria bancrofti
infection and of pulmonary embolism caused by the cystic
stage of the tapeworm Echinococcus granulosus (hydatid cyst)
with PH have been reported [46]. Studies on prevalence and
pathogenesis in endemic regions will unveil further detail in
the future.
In summary, it is clear that there is an association of infec-
tions with pulmonary vascular pathology. Although advances
continue to be made in understanding HIV-associated and
Schistosomiasis-associated PAH, the precise pathomechanism
is as yet unclear, and future investigations should focus more
on cellular and molecular mechanisms. Other infections that
have potential associations with pulmonary vascular diseases
deserve further study with regard to their natural history
and pathobiology.
Inﬂammation as a Therapeutic Target in
PH
The connection between inﬂammation and PH is now gen-
erally accepted, but several questions remain. Several
important issues have to be resolved in the future: ﬁrst, it
is unclear whether inﬂammation is sufﬁcient for the deve-
lopment of PH; second, what are the reasons for this high
and/or low frequency of immune and inﬂammatory cells in
IPAH tissue; and third, does this have pathological and/or
clinical implications? A better understanding of the mecha-
nisms that link immune and inﬂammatory cells, abnormal
angiogenesis and pulmonary artery remodelling in PH is
needed.
Our understanding of the pivotal role of inﬂammation in
the pathogenesis of PH opens opportunities in biomarker
assessment and therapy for this disease. For example, lev-
els of circulating inﬂammatory markers such as C-reactive
protein are increased in chronic thrmoboembolic PH and
PAH patients as compared with control subjects, predicting
the outcome and response to therapy in PAH [47]. The
relevance of inﬂammatory mechanisms in some individuals
with severe PAH has been further suggested by the clinical
improvement of a subset of patients after corticosteroid
or immunosuppressive therapy [48]. In addition, some
classes of drugs, such as prostacyclins, approved for the
treatment of PAH, and inhibitors of hydroxymethylglutaryl
coenzyme A (statins), recently used in clinical trials, were
shown to have anti-inﬂammatory and immunomodulatory
functions [49,50]. These examples provide illustrations of
unexpected anti-inﬂammatory effects of existing therapies
for PH. Uncovering inﬂammatory pathways has raised the
possibility that future treatments may target effectors of
inﬂammation directly, to add to the beneﬁt of current
treatments.
Conclusions
It is now evident that inﬂammation plays a prominent role
in the initiation/development of PH. The inﬂammatory
cells, and the chemokines and cytokines that they produce,
inﬂuence the pulmonary vasculature, and regulate the
growth, migration and differentiation of all cell types, thus
leading to vascular remodelling. However, many of the
molecular and cellular mechanisms remain unresolved.
New insights into inﬂammation in PH may identify inno-
vative therapeutic strategies for the treatment of this dev-
astating disease.
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